Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19
Journal
Journal of nanobiotechnology
Journal Volume
22
Journal Issue
1
Date Issued
2024-04-12
Author(s)
Fang, Jia-You
Huang, Kuo-Yen
Wang, Tong-Hong
Lin, Zih-Chan
Chen, Chin-Chuan
Chen, En-Li
Yang, Shuenn-Chen
Chen, Chi-Yuan
Abstract
Angiotensin-converting enzyme 2 (ACE2) and AXL tyrosine kinase receptor are known to be involved in the SARS-CoV-2 entry of the host cell. Therefore, targeting ACE2 and AXL should be an effective strategy to inhibit virus entry into cells. However, developing agents that can simultaneously target ACE2 and AXL remains a formidable task. The natural compound quercetin has been shown to inhibit AXL expression.
Subjects
ACE2; AXL; COVID-19; Nanoparticles; Quercetin
SDGs
Type
journal article